Edge Therapeutics, Inc     Print Page | Close Window

Investors

Corporate Profile

Edge Therapeutics is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening conditions.

We believe EG-1962, our lead product candidate, can fundamentally improve patient outcomes and transform the management of aneurysmal subarachnoid hemorrhage, or aSAH, which is bleeding around the brain due to a ruptured brain aneurysm. Read More

Lastest News

June 15, 2017 - Edge Therapeutics to Participate in the JMP Securities Life Science Conference
Read More
June 8, 2017 - Edge Therapeutics Receives Pediatric Investigation Plan Waiver from the European Medicines Agency
Read More
June 2, 2017 - Edge Therapeutics to Present at Jefferies 2017 Global Healthcare Conference
Read More

Upcoming Events

There are currently no events scheduled.

More >>

Stock Information

EDGE (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$10.27
Change (%) Stock is Down 0.03 (0.00%)
Volume28,999
Data as of June 22, 2017 4:00 p.m. ET
Refresh quote

IR Contact

Gregory Gin
Email: ir@edgetherapeutics.com

Data provided by Nasdaq. Minimum 15 minutes delayed.